P/E ratio for Novocure (NVCR)
P/E ratio as of July 2025 (TTM): -7.53
According to Novocure 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.53311. At the end of 2024 the company had a P/E ratio of -19.1.
P/E ratio history for Novocure from 2015 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -19.1 | 149.5% |
| 2023 | -7.66 | -90.81% |
| 2022 | -83.4 | -37.83% |
| 2021 | -134 | -115.5% |
| 2020 | 865 | -182.14% |
| 2019 | < -1000 | 2102.4% |
| 2018 | -47.8 | 65.74% |
| 2017 | -28.9 | 469.79% |
| 2016 | -5.06 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novocure
NVCR | -7.53 | 0.00% | Jersey |
 Novavax NVAX | 2.31 | -130.61% | 🇺🇸 USA |
 Organovo ONVO | -0.1771 | -97.65% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | -2.69 | -64.24% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.